A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.
- D. Fouque, K. Kalantar-Zadeh, C. Wanner
- Medicine, BiologyKidney International
- 2 February 2008
An expert panel to review and develop standard terminologies and definitions related to wasting, cachexia, malnutrition, and inflammation in CKD and AKI recommends the term 'protein-energy wasting' for loss of body protein mass and fuel reserves.
A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients.
- K. Kalantar-Zadeh, J. Kopple, G. Block, M. Humphreys
- MedicineAmerican Journal of Kidney Diseases
- 1 December 2001
The MIS appears to be a comprehensive scoring system with significant associations with prospective hospitalization and mortality, as well as measures of nutrition, inflammation, and anemia in MHD patients, and may be superior to the conventional SGA and the DMS as a predictor of dialysis outcome and an indicator of MICS.
Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences.
- K. Kalantar-Zadeh, T. Ikizler, G. Block, M. Avram, J. Kopple
- Medicine, BiologyAmerican Journal of Kidney Diseases
- 1 November 2003
National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure.
- J. Kopple
- Medicine, BiologyAmerican Journal of Kidney Diseases
- 2001
A number of the more prominent clinical practice guidelines for the adults are discussed, including the recommendation that the protein-energy nutritional status in patients with advanced chronic renal failure should be assessed by a panel of measures rather than by any single measure.
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.
- K. Kalantar-Zadeh, N. Kuwae, J. Kopple
- MedicineKidney International
- 2 August 2006
Associations between high serum parathyroid hormone and increased death risk were masked by case-mix characteristics of MHD patients, and Administration of any dose of paricalcitol was associated with improved survival in time-varying models.
Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis.
- K. Kalantar-Zadeh, J. Kopple, G. Block, M. Humphreys
- MedicineJournal of the American Society of Nephrology
- 1 December 2001
In patients on MHD the SF36 appears to have significant associations with measures of nutritional status, anemia, and clinical outcomes, including prospective hospitalization and mortality, even though obesity, unlike undernutrition, is not generally an indicator of poor outcome in MHD.
Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients.
- K. Kalantar-Zadeh, G. Block, M. Humphreys, J. Kopple
- Medicine, BiologyKidney International
- 1 March 2003
An inverse association between conventional risk factors and clinical outcome in dialysis patients is found and it is possible that new standards or goals for such traditional risk factors as body mass, serum cholesterol, and blood pressure should be considered for these individuals.
KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update.
- T. Ikizler, J. Burrowes, L. Cuppari
- MedicineAmerican Journal of Kidney Diseases
- 1 September 2020
The 2020 update to the KDOQI Clinical Practice Guideline for Nutrition in CKD provides comprehensive up-to-date information on the understanding and care of patients with chronic kidney disease (CKD), especially in terms of their metabolic and nutritional milieu for the practicing clinician and allied health care workers.
Kinetic analysis of lead metabolism in healthy humans.
- M. Rabinowitz, G. Wetherill, J. Kopple
- MedicineJournal of Clinical Investigation
- 1 August 1976
The steady state kinetics of lead metabolism were studied in five healthy men with stable isotope tracers and the data suggest a three compartmental model for lead metabolism.
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria.
...
...